Delpor is a clinical-stage biopharmaceutical company dedicated to revolutionizing the treatment of chronic diseases through the development of once-yearly therapies. With a focus on central nervous system (CNS) conditions such as Schizophrenia, Opioid Use Disorder, Spasticity, Parkinson’s, Alzheimer’s, and MS, Delpor utilizes innovative technologies to create long-acting implantable devices. Their cutting-edge technologies, including Prozor TM and Nanopor TM, enable the controlled release of medication, eliminating the need for frequent dosing and reducing the risk of medication non-adherence.

These devices offer a convenient and efficient alternative to traditional depot formulations and other subcutaneous (SQ) implants. Delpor's product portfolio includes DLP-114, DLP-160, and DLP-208, all designed to provide therapeutic benefits for specific diseases. Driven by a mission to improve patient outcomes and quality of life, Delpor aims to make once-yearly therapies the standard care for chronic diseases.

With a dedicated team of officers and directors, led by the CEO, Delpor is committed to transforming the way we manage and treat chronic conditions. Explore their website for more information on their innovative technologies, partnerships, and career opportunities